Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer

References

• Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021;41(11):1183–1194.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Mansour A, Jaddan D. Breast Cancer Care in Jordan. JCO Glob Oncol. 2020;6:260–268.
   PubMedGoogle Scholar
• Abdel-Razeq H, Tamimi F, Abdel-Razeq N, et al. Late presentation and suboptimal treatment of breast cancer among Syrian refugees: a retrospective study. J Int Med Res. 2021;49(5):3000605211018448.
   Web of Science ®Google Scholar
• Liede A, Jerzak KJ, Hernandez RK, Wade SW, Sun P, Narod SA. The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat. 2016;156(3):587–595.
   PubMed Web of Science ®Google Scholar
• Manders K, van de Poll-Franse LV, Creemers GJ, et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer. 2006;6(1):1–8.
   PubMed Web of Science ®Google Scholar
• Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61–66.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(Suppl 8):1588–1594.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s–6249s.
   PubMed Web of Science ®Google Scholar
• Parkes A, Warneke CL, Clifton K, et al. Prognostic factors in patients with metastatic breast cancer with bone-only metastases. Oncologist. 2018;23(11):1282–1288.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Cramarossa G, Chow E, Zhang L, et al. Predictive factors for overall quality of life in patients with advanced cancer. Support Care Cancer. 2013;21:1709–1716.
   PubMed Web of Science ®Google Scholar
• Caissie A, Culleton S, Nguyen J, et al. EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy. Support Care Cancer. 2012;20(4):841–848.
   PubMed Web of Science ®Google Scholar
• Rossi L, Longhitano C, Kola F, Del Grande M. State of art and advances on the treatment of bone metastases from breast cancer: a concise review. Chin Clin Oncol. 2020;9(2):18.
   PubMed Web of Science ®Google Scholar
• Schurman DJ, Amstutz HC. Orthopedic management of patients with metastatic carcinoma of the breast. Surg Gynecol Obstet. 1973;137(5):831–836.
   PubMedGoogle Scholar
• Pretell J, Rodriguez J, Blanco D, Zafra A, Resines C. Treatment of pathological humeral shaft fractures with intramedullary nailing. A retrospective study. Int Orthop. 2010;34(4):559–563.
   PubMed Web of Science ®Google Scholar
• Kim WS, Kim KH. Percutaneous osteoplasty for painful bony lesions: a technical survey. Korean J Pain. 2021;34(4):375–393.
   PubMed Web of Science ®Google Scholar
• Brooks GA, Landrum MB, Kapadia NS, et al. Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment. J Clin Oncol. 2022;1:JCO2102342.
   Google Scholar
• Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000;36(4):476–482.
   PubMed Web of Science ®Google Scholar
• Tahara RK, Brewer TM, Theriault RL, Ueno NT. Bone Metastasis of Breast Cancer. Adv Exp Med Biol. 2019;1152:105–129.
   PubMed Web of Science ®Google Scholar
• Cummings MC, Simpson PT, Reid LE, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232(1):23–31.
   PubMed Web of Science ®Google Scholar
• Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23(3):175–180.
   PubMed Web of Science ®Google Scholar
• Mercatali L, Spadazzi C, Miserocchi G, et al. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. Int J Mol Sci. 2016;17(11):1827.
   PubMed Web of Science ®Google Scholar
• Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–549.
   PubMed Web of Science ®Google Scholar
• Mercatali L, La Manna F, Miserocchi G, et al. Tumor-Stroma Crosstalk in Bone Tissue: the Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. Int J Mol Sci. 2017;18(8):1655.
   PubMed Web of Science ®Google Scholar
• Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369.
   PubMed Web of Science ®Google Scholar
• Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009;9(1):39–44.
   PubMed Web of Science ®Google Scholar
• Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, Phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–998.
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208–217.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a Phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489–498.
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014;2014(6):847.
   Google Scholar
• Sledge GW, Hu P, Falkson G, Tormey D, Abeloff M. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2000;18(2):262–266.
   PubMed Web of Science ®Google Scholar
• Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: primary Results From the Phase III MARIANNE Study. J Clin Oncol. 2017;35(2):141–148.
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742.
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597–609.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573–584.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Park S, Ahn HK, et al. Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat. 2011;43(2):89–95.
   PubMed Web of Science ®Google Scholar
• Litière S, Isaac G, De Vries EGE, et al. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: a Pooled Database Analysis. J Clin Oncol. 2019;37(13):1102–1110.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang J, Li Z, Wu Y, Tong Z. Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis. Oncol Lett. 2020;20(4):92.
   PubMed Web of Science ®Google Scholar
• Curtit E, Bazan F, Chaigneau L, et al. Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer. Ann Oncol. 2018;29(suppl):8).
   Google Scholar
• Ahn SG, Lee HM, Cho SH, et al. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J. 2013;54(5):1168–1177.
   PubMed Web of Science ®Google Scholar
• Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77(2):336–340.
   PubMed Web of Science ®Google Scholar
• Bertho M, Fraisse J, Patsouris A, et al. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol. 2021;21:13.
   Google Scholar
• McKenzie HS, Maishman T, Simmonds P, et al. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients. Br J Cancer. 2020;122(11):1618–1629.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Brufsky A, Cobleigh M, et al. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020;25(2):e214–e222.
   PubMed Web of Science ®Google Scholar
• Yamamura J, Kamigaki S, Fujita J, Osato H, Komoike Y. the difference in prognostic outcomes between de novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2-negative breast cancer. Vivo. 2018;32(2):353–358.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139.
   PubMed Web of Science ®Google Scholar
• Parkes A, Clifton K, Al-Awadhi A, et al. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018;4(2):1–7.
   PubMedGoogle Scholar
• Emi Y, Kitamura K, Shikada Y, Kakeji Y, Takahashi I, Tsutsui S. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery. 2002;131(Suppl 1):S217–S221.
   PubMed Web of Science ®Google Scholar
• Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17(3):173–176.
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21(11):2169–2174.
   PubMed Web of Science ®Google Scholar